{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:25:32Z","timestamp":1792275932630,"version":"4.4.0"},"reference-count":108,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Primary cutaneous B-cell lymphomas (PCBCL) are a rare and heterogeneous group of non-Hodgkin lymphomas that are confined to the skin at diagnosis and exhibit a tendency for cutaneous recurrence. The 5th edition of the World Health Organization and the 2022 International Consensus Classification recognize three main subtypes: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma\/lymphoproliferative disorder (PCMZL\/LPD), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL,LT). These subtypes differ in clinical behavior, histopathologic features, immunophenotype, and molecular alterations. Diagnosis and management remain challenging for clinicians. This review aims to provide a comprehensive overview of the defining features and current treatment strategies for PCBCL. Methods: This narrative review synthesizes current literature on the clinical, morphologic, immunohistochemical, and molecular characteristics of PCBCL. It also evaluates the diagnostic utility of immunohistochemistry, gene expression profiling, and molecular assays, particularly in distinguishing primary cutaneous disease from secondary cutaneous involvement by systemic lymphomas. Results: PCFCL arises from germinal center B-cells and must be differentiated from nodal follicular lymphoma. PCMZL\/LPD is derived from post-germinal center B-cells and is often linked to chronic antigenic stimulation. Both PCFCL and PCMZL\/LPD are indolent and associated with favorable outcomes. By contrast, PCDLBCL,LT is an aggressive lymphoma characterized by genetic alterations activating the NF-\u03baB pathway, commonly including mutations to MYD88 and CD79B. Treatment strategies vary by subtype, ranging from localized therapies for indolent lymphomas to systemic chemoimmunotherapy for aggressive PCBCL. Emerging therapies, such as Bruton tyrosine kinase inhibitors and immunoregulatory agents, are being investigated for relapsed\/refractory disease. Conclusions: PCBCL encompass distinct clinicopathologic entities with subtype-specific diagnostic and therapeutic considerations. While current management is guided by clinical behavior, significant knowledge gaps remain regarding the molecular mechanisms underlying skin tropism, immune evasion, and disease progression. Future research could focus on improving molecular characterization and developing personalized and immune-based therapies to enhance outcomes. This review consolidates current knowledge and highlights innovations aimed at advancing the diagnosis and treatment of PCBCL in clinical practice.<\/jats:p>","DOI":"10.3390\/cancers17071202","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:29:19Z","timestamp":1743485359000},"page":"1202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Unveiling Primary Cutaneous B-Cell Lymphomas: New Insights into Diagnosis and Treatment Strategies"],"prefix":"10.3390","volume":"17","author":[{"given":"Zachary R.","family":"Barbati","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California San Francisco, San Francisco, CA 94107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Charli-Joseph","sequence":"additional","affiliation":[{"name":"Dermatology and Dermatopathology Private Practice, Mexico City 01090, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.det.2022.07.014","article-title":"A Practical Review of the Presentation, Diagnosis, and Management of Cutaneous B-Cell Lymphomas","volume":"41","author":"Goyal","year":"2023","journal-title":"Dermatol. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4103\/0019-5154.185698","article-title":"Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?","volume":"61","author":"Pincus","year":"2016","journal-title":"Indian J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.hoc.2024.05.017","article-title":"Cutaneous B-Cell Lymphomas","volume":"38","author":"Chung","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"329.e1","DOI":"10.1016\/j.jaad.2013.06.012","article-title":"Primary cutaneous B-cell lymphomas: Part I. Clinical features, diagnosis, and classification","volume":"69","author":"Pulitzer","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/jdv.19987","article-title":"Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group","volume":"38","author":"Kempf","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","unstructured":"National Comprehensive Cancer Network (2025, March 16). Clinical Practice Guidelines in Oncology. Primary Cutaneous Lymphomas (Version 1.25). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf."},{"key":"ref_10","first-page":"61","article-title":"Approach to dermal-based lymphoid infiltrates and proliferations","volume":"37","year":"2018","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.clml.2021.10.009","article-title":"Characterization of Primary and Secondary Cutaneous B-Cell Lymphomas: A Population-Based Study of 4758 Patients","volume":"22","author":"Leary","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: Recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdermsci.2020.01.010","article-title":"Cutaneous lymphoma in Japan, 2012-2017: A nationwide study","volume":"97","author":"Fujii","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Moon, I.J., Won, C.H., Chang, S.E., Park, C.S., Yoon, D.H., Song, S.Y., Lee, M.W., and Lee, W.J. (2024). Prevalence, clinical features, and survival outcome trends of 627 patients with primary cutaneous lymphoma over 29 years: A retrospective review from single tertiary center in Korea. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-71210-y"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.5858\/arpa.2018-0215-RA","article-title":"Primary Cutaneous Follicle Center Lymphoma","volume":"142","author":"Skala","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Italian Study Group for Cutaneous Lymphomas. Prognostic factors in primary cutaneous B-cell lymphoma: The Italian Study Group for Cutaneous Lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2133.2012.11122.x","article-title":"Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: Prognosis of subtypes defined in the WHO-EORTC classification","volume":"167","author":"Bessell","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.2001.19.16.3602","article-title":"Prognostic factors in primary cutaneous large B-cell lymphomas: A European multicenter study","volume":"19","author":"Grange","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_21","first-page":"432","article-title":"Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma","volume":"137","author":"Bergman","year":"2001","journal-title":"Arch. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaad.2010.07.035","article-title":"Miliary and agminated-type primary cutaneous follicle center lymphoma: Report of 18 cases","volume":"65","author":"Massone","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaad.2010.06.059","article-title":"Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: Implications for early diagnosis and treatment","volume":"65","author":"Gulia","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","first-page":"1334","article-title":"Low-Grade Cutaneous B-cell Lymphoma in African American Patients","volume":"17","author":"Geller","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: Comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/PAS.0000000000000388","article-title":"Cutaneous Spindle-Cell B-Cell Lymphomas: Most are Neoplasms of Follicular Center Cell Origin","volume":"39","author":"Cerroni","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Cerroni, L. (2020). Skin Lymphoma: The Illustrated Guide, John Wiley & Sons. [5th ed.].","DOI":"10.1002\/9781119485933"},{"key":"ref_28","unstructured":"Gru, A., and Schaffer, A. (2023). Hematopathology of the Skin: A Clinical and Practical Approach, Lippincott Williams & Wilkins. [2nd ed.]."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","article-title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.2005.02.0842","article-title":"Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma","volume":"24","author":"Dijkman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/bloodadvances.2020002469","article-title":"Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features","volume":"5","author":"Zhou","year":"2021","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00000478-200206000-00006","article-title":"Primary cutaneous follicular lymphoma: A clinicopathologic and molecular study of 16 cases in support of a distinct entity","volume":"26","author":"Goodlad","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1365-2133.2001.04128.x","article-title":"Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma","volume":"144","author":"Child","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.humpath.2020.09.014","article-title":"The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma","volume":"106","author":"Barasch","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaad.2014.01.862","article-title":"Chromosomal anomalies in primary cutaneous follicle center cell lymphoma do not portend a poor prognosis","volume":"70","author":"Tang","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","article-title":"Primary cutaneous marginal zone B-cell lymphoma: Response to treatment and disease-free survival in a series of 137 patients","volume":"69","author":"Servitje","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","article-title":"Primary cutaneous marginal zone B-cell lymphoma: Clinical and therapeutic features in 50 cases","volume":"141","author":"Hoefnagel","year":"2005","journal-title":"Arch. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/DAD.0b013e318289b20e","article-title":"Cutaneous lymphomas: An update. Part 2: B-cell lymphomas and related conditions","volume":"36","author":"Kempf","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archdermatol.2009.340","article-title":"Anetodermic primary cutaneous B-cell lymphoma: A unique clinicopathological presentation of lymphoma possibly associated with antiphospholipid antibodies","volume":"146","author":"Hodak","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jdcr.2017.06.024","article-title":"Epidermotropic marginal zone lymphoma: An uncommon cutaneous B-cell lymphoma responsive to rituximab","volume":"3","author":"Magro","year":"2017","journal-title":"JAAD Case Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/DAD.0000000000000022","article-title":"Clonality assessment of cutaneous B-cell lymphoid proliferations: A comparison of flow cytometry immunophenotyping, molecular studies, and immunohistochemistry\/in situ hybridization and review of the literature","volume":"36","author":"Schafernak","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/PAS.0b013e3181f72835","article-title":"Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets","volume":"34","author":"Edinger","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1182\/blood-2008-01-132415","article-title":"The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment","volume":"112","author":"Wormhoudt","year":"2008","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/PAS.0000000000001363","article-title":"Class-switched Primary Cutaneous Marginal Zone Lymphomas Are Frequently IgG4-positive and Have Features Distinct from IgM-positive Cases","volume":"43","author":"Carlsen","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/jid.2008.243","article-title":"Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation","volume":"129","author":"Deutsch","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2133.2009.09576.x","article-title":"Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments","volume":"162","author":"Perez","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/modpathol.2008.159","article-title":"Primary cutaneous marginal zone B-cell lymphoma: A molecular and clinicopathological study of cases from Asia, Germany, and the United States","volume":"21","author":"Takino","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/10428190802064925","article-title":"Primary cutaneous B-cell lymphomas\u2014Clinicopathological, prognostic and therapeutic characterization of 54 cases according to the WHO-EORTC classification and the ISCL\/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome","volume":"49","author":"Golling","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1634\/theoncologist.2015-0175","article-title":"Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University","volume":"20","author":"Haverkos","year":"2015","journal-title":"Oncologist"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaad.2017.07.053","article-title":"Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study","volume":"78","author":"Goyal","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/10428190500399698","article-title":"Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma","volume":"47","author":"Cozzio","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: Field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2133.2010.09798.x","article-title":"Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma","volume":"163","author":"Perry","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"13030\/qt9s15929m","DOI":"10.5070\/D3218028432","article-title":"A case report of primary cutaneous marginal zone lymphoma treated with intralesional steroids","volume":"21","author":"Kollipara","year":"2015","journal-title":"Dermatol. Online J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1634\/theoncologist.2011-0108","article-title":"Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas","volume":"16","author":"Ponzoni","year":"2011","journal-title":"Oncologist"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1034\/j.1600-0560.2001.281002.x","article-title":"Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States","volume":"28","author":"Wood","year":"2001","journal-title":"J. Cutan. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/archderm.138.11.1421","article-title":"Topical targretin and intralesional interferon alfa for cutaneous lymphoma of the scalp","volume":"138","author":"Trent","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","article-title":"Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: Report and follow-up of eight cases","volume":"155","author":"Kerl","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archderm.136.3.374","article-title":"Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma","volume":"136","author":"Heinzerling","year":"2000","journal-title":"Arch. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-0609.2006.00720.x","article-title":"Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab","volume":"77","author":"Kyrtsonis","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H","article-title":"Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma","volume":"89","author":"Heinzerling","year":"2000","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2133.2005.06659.x","article-title":"Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation","volume":"153","author":"Gellrich","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaad.2008.08.005","article-title":"Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab","volume":"59","author":"Morales","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/annonc\/mdn636","article-title":"Rituximab monotherapy for primary cutaneous B-cell lymphoma: Response and follow-up in 16 patients","volume":"20","author":"Valencak","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.12484","article-title":"Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas","volume":"169","author":"Brandenburg","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Vitiello, P., Sica, A., Ronchi, A., Caccavale, S., Franco, R., and Argenziano, G. (2020). Primary Cutaneous B-Cell Lymphomas: An Update. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00651"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/modpathol.2008.40","article-title":"Primary cutaneous CD4-positive small\/medium-sized pleomorphic T-cell lymphoma: A clonal T-cell lymphoproliferative disorder with indolent behavior","volume":"21","author":"Grogg","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/PAS.0b013e31818e52fe","article-title":"Primary cutaneous CD4+ small\/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers","volume":"33","author":"Roncador","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/DAD.0b013e31819f19bb","article-title":"Primary cutaneous CD4+ small-\/medium-sized pleomorphic T-cell lymphoma: A cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases","volume":"31","author":"Beltraminelli","year":"2009","journal-title":"Am. J. Dermatopathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaad.2010.07.028","article-title":"Reappraisal of the provisional entity primary cutaneous CD4+ small\/medium pleomorphic T-cell lymphoma: A series of 10 adult and pediatric patients and review of the literature","volume":"65","author":"Baum","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/PAS.0b013e318230df87","article-title":"Expression of programmed death-1 in primary cutaneous CD4-positive small\/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma","volume":"36","author":"Jansen","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/cup.12806","article-title":"Clinicopathological and molecular study of primary cutaneous CD4+ small\/medium-sized pleomorphic T-cell lymphoma","volume":"43","author":"Talpur","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1111\/jdv.18287","article-title":"BCL-2 expression in primary cutaneous follicle center lymphoma is associated with a higher risk of cutaneous relapses: A study of 126 cases","volume":"36","author":"Pileri","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ronchi, A., Vitiello, P., D\u2019Abbronzo, G., Caccavale, S., Argenziano, G., Sica, A., Alfan, R., Savarese, G., Berretta, M., and Cozzolino, I. (2023). Primary Cutaneous B-Cell Lymphomas with Large Cell Morphology: A Practical Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076204"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type: Clinicopathologic features and prognostic analysis in 60 cases","volume":"143","author":"Grange","year":"2007","journal-title":"Arch. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","article-title":"Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group","volume":"132","author":"Vermeer","year":"1996","journal-title":"Arch. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamadermatol.2013.7452","article-title":"Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France","volume":"150","author":"Grange","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hon.2919","article-title":"Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"39","author":"Kraft","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0190-9622(87)70068-1","article-title":"Primary cutaneous large cell lymphomas of follicular center cell origin. A clinical follow-up study of nineteen patients","volume":"16","author":"Willemze","year":"1987","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00428-021-03265-5","article-title":"Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas","volume":"480","author":"Schrader","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.mpdhp.2024.05.002","article-title":"New insights and advances in defining primary cutaneous B-cell lymphomas and cutaneous B-cell-rich lymphoid proliferations","volume":"30","year":"2024","journal-title":"Diagn. Histopathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jdermsci.2017.07.008","article-title":"Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type","volume":"88","author":"Deveza","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Schrader, A.M.R., de Groen, R.A.L., Willemze, R., Jansen, P.M., Quint, K.D., Cleven, A.H.G., van Wezel, T., van Eijk, R., Ruano, D., and Veelken, J.H.H. (2022). Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring. Cancers, 14.","DOI":"10.3390\/cancers14205152"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/jid.2008.357","article-title":"Fine-mapping chromosomal loss at 9p21: Correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"129","author":"Senff","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/PAS.0000000000001132","article-title":"High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","volume":"42","author":"Schrader","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/modpathol.2013.156","article-title":"Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma","volume":"27","author":"Andrique","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41379-018-0041-7","article-title":"Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas","volume":"31","author":"Menguy","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2021.01.006","article-title":"Double expressor and double\/triple hit status among primary cutaneous diffuse large B-cell lymphoma: A comparison between leg type and not otherwise specified subtypes","volume":"111","author":"Lucioni","year":"2021","journal-title":"Hum. Pathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"115064","DOI":"10.1016\/j.ejca.2024.115064","article-title":"Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group","volume":"212","author":"Elsayad","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_91","unstructured":"National Comprehensive Cancer Network (2025, February 18). Clinical Practice Guidelines in Oncology. B-Cell Lymphomas (Version 2.25). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000534784","article-title":"Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report","volume":"69","author":"Zoli","year":"2024","journal-title":"Chemotherapy"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.3324\/haematol.2016.161893","article-title":"Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79","volume":"102","author":"Deng","year":"2017","journal-title":"Haematologica"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.4081\/rt.2015.6067","article-title":"Excellent Outcome of Immunomodulation or Bruton\u2019s Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","volume":"7","author":"Gupta","year":"2015","journal-title":"Rare Tumors"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s00277-022-04899-4","article-title":"Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type","volume":"101","author":"Oka","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_96","unstructured":"Bandali, T. (2024, January 11\u201313). Treatment of primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) in the modern era, Abstract. Proceedings of the 5th World Congress of Cutaneous Lymphomas, Pasadena, CA, USA."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jid.2018.03.1516","article-title":"A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type","volume":"138","author":"Mermin","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: A paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41824-023-00174-5","article-title":"F-18 FDG PET\/CT in staging and response assessment of primary cutaneous diffuse large B-cell lymphoma (leg type)","volume":"7","author":"Datta","year":"2023","journal-title":"Eur. J. Hybrid Imaging"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jid.2024.07.025","article-title":"Detection of Circulating Tumor DNA for Disease Monitoring in Patients with Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","volume":"145","author":"Schrader","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/1346-8138.17339","article-title":"Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type: A case series and review of the literature","volume":"51","author":"Winkler","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"152","DOI":"10.21147\/j.issn.1000-9604.2019.01.10","article-title":"Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China","volume":"31","author":"Shi","year":"2019","journal-title":"Chin. J. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.jid.2019.05.008","article-title":"Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type","volume":"139","author":"Ducharme","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jid.2018.04.038","article-title":"Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type","volume":"138","author":"Zhou","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.it.2014.12.006","article-title":"Revisiting the role of B cells in skin immune surveillance","volume":"36","author":"Egbuniwe","year":"2015","journal-title":"Trends Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:07:41Z","timestamp":1760029661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":108,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071202"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071202","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}